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Abstract The aim of this study was to investigate the influ-
ence of theMultiwave Locked System (MLS) laser therapy on
clinical features, microvascular changes in nailfold
videocapillaroscopy (NVC) and circulating modulators re-
leasing as a consequence of vascular endothelium injury such
as vascular endothelial growth factor (VEGF) and
angiopoietin 2 (Ang-2) in patients with primary and secondary
Raynaud’s phenomenon. Seventy-eight RP patients and 30
healthy volunteers were recruited into the study. All patients
with RP received MLS laser irradiation for 3 weeks. Clinical,
NVC and laboratory investigations were performed before
and after the MLS laser therapy. The serum concentration of
VEGF and Ang-2 were determined by an enzyme-linked
immunosorbent assay (ELISA). After 3 weeks of MLS laser
therapy, the clinical improvement manifested by decreasing of
the number of RP attacks, mean duration of Raynaud’s attack
and pain intensity in RP patients was observed. After MLS
laser therapy in 65 % of patients with primary and in 35 %
with secondary RP, an increase in the loop number and/or a
reduction in avascular areas in NVC were observed. In com-
parison with a control group, higher serum concentration of
VEGF and Ang-2 in RP patients was demonstrated. After
MLS laser therapy, a reduction of Ang-2 in both groups of
RP patients was found. Our results suggest that NVC may
reflect microvascular changes associated with clinical im-
provement after MLS laser therapy in patients with primary
and secondary RP. Ang-2 serum levels may be a useful marker
of microvascular abnormalities in RP patients treated with
MLS laser therapy.
Keywords Angiogenesismodulators . Multiwave Locked
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(NVC) . Raynaud’s phenomenon
Abbreviations
RP Raynaud’s phenomenon
MLS Multiwave Locked System
NVC Nailfold videocapillaroscopy
VEGF Vascular endothelial growth factor and Ang-2,
angiopoietin-2
Introduction
Raynaud’s phenomenon (RP) is a vascular disorder char-
acterized by recurrent vasospastic response of the fingers
and toes to cold or emotional stimuli. It can be primary
(idiopathic) or secondary (Raynaud’s syndrome) related to
a number of different pathological conditions, including
rheumatic diseases [1].
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Although the pathogenesis of RP is poorly understood,
current data points to three main pathophysiological mecha-
nisms: vascular abnormalities, disturbances in the neural con-
trol of vascular tone and intravascular factors including circu-
lating mediators and they influence on the balance between
vasoconstriction and vasodilatation [2]. Angiogenic factors
such as vascular endothelial growth factor (VEGF) and
angiopoietin-2 (Ang-2) are the main regulators of angiogene-
sis, playing an essential role in vascular remodelling [3, 4].
Ang-2 as an autocrine mediator of the endothelium makes the
vessel hypersensitive to the effects of pro-inflammatory cyto-
kines and VEGF, resulting in vessel destabilization [5, 6].
Furthermore, it has been shown that VEGF and Ang-2
reflected the dysregulation of endothelium, leading to the
development of the main clinical manifestations in patients
with systemic sclerosis [7].
RP is a vascular disorder that involves digital arteries, pre-
capillary arterioles and subcutaneous arteriovenous shunts,
leading to the microvascular abnormalities with a broad spec-
trum of clinical manifestations. According to recent studies,
microvascular abnormalities, manifested as RP, can be a pre-
dictor of severe underlying disease with reduced life expec-
tancy [1]. Nailfold videocapillaroscopy (NVC) has been pro-
posed as a first-line investigation in the early differential
diagnosis of RP and connective tissue diseases [8–10]. In
our previous studies, we demonstrated the usefulness of
NVC as a non-invasive method for the evaluation of micro-
vascular involvement in patients with systemic lupus erythe-
matosus (SLE), rheumatoid arthritis (RA) and other connec-
tive tissue diseases (CTD) [11, 12].
Although new approaches to the pathogenesis and early
diagnosis of RP are continually improving, still no universal
guidelines for the treatment of RP exist. Treatment for RP
depends on its severity and for mild disease is generally
conservative [12]. The results of standard treatment for RP
showed a weak improvement due to side effects and poor
compliance [13, 14]. Therefore, searching for non-
pharmacologic treatment methods is the focus of many recent
studies [15].
Laser therapy in low doses has a beneficial effect in patients
with primary and secondary RP [16]. It has been demonstrated
that low-level laser therapy reduces significantly the frequen-
cy and severity of vasospastic attacks, but the mechanism of
action and the degree of improvement of laser biostimulation
in RP patients remain unclear [17].
Multiwave Locked System (MLS) laser therapy, character-
ized by a synchronized emissions of two wavelengths of
808 nm (in continuous mode) and 905 nm (as a pulsed laser
light), is a new technique used in order to increase the effect of
laser irradiation [18]. Two emissions are absorbed by different
mitochondrial complexes and can affect cellular energy me-
tabolism by acting on multiple sites in the cellular respiratory
chain at the same time. Continuous emission is absorbed by
the cytochrome oxidase which activation promotes the pro-
duction of ATP, leading to the anti-inflammatory and anti-
oedematous effects by stimulating microcirculation and
influencing on the synthesis and degradation of inflammatory
mediators [19]. Pulsed emission reduces pain through an
effect on the superficial nociceptors and afferent nervous
fibres, influencing on the nerve conduction [20]. The result
of this emission is an increase of the nociceptive threshold and
in a consequence—a reduction of pain sensation. Synchroni-
zation of both radiation components intensifies the analgesic,
anti-inflammatory and anti-oedematous effect, increasing the
intensity of the therapeutic effect on both pain and inflamma-
tion [19, 21]. Therefore, it is possible that MLS radiation can
interact with deep located tissue and influence on the perme-
ability of the cellular membrane, vessel walls (anti-inflamma-
tory and anti-edematous effect) and peripheral nervous system
(analgesic effect).
Despite the growing interest in MLS laser therapy as a new
treatment method, the mechanisms underlying the effect on
microcirculation in patients with RP are unclear. Therefore,
the aim of this study was to investigate the influence of MLS
laser therapy on clinical features, microvascular changes in
nailfold videocapillaroscopy and circulating modulators re-
leasing as a consequence of vascular endothelium injury such
as VEGF and Ang-2 in patients with primary and secondary
Raynaud’s phenomenon.
According to our knowledge, the present study is the first
analysis of the influence of MLS laser therapy on microvas-




Seventy-eight outpatients with RP (75 women and 3 men;
mean age 42.8 years, range 19–77) of the Department of
Rehabilitation of the Medical University of Bialystok,
Bialystok, Poland, were recruited into the study. All RP pa-
tients were classified into two groups, those with primary RP,
38 cases (including 36 women and 2 men; mean age
36.5 years, range 19–77), fulfilling the criteria of LeRoy and
Medsger [22], exhibited exclusively Raynaud’s phenomenon
without any clinical or laboratory signs of the presence of a
systemic autoimmune disease and 40 patients with secondary
RP (39 women and 1 man; mean age 48.9 years, range 26–
66). Patients with primary RP had absence of NVC scleroder-
ma pattern and negative findings of autoantibody assays [22].
The group of secondary RP included 28 patients with systemic
sclerosis (SSc), six patients with systemic lupus erythemato-
sus (SLE) and six cases with undifferentiated connective
tissue disease (UCTD), according to the international criteria
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[23–26]. Patients with the history of previous contact with
vasodilators or immunosuppressive therapy with cyclosporine
or cyclophosphamide, which could influence on the micro-
vasculature, were excluded [27]. The characteristics of the
patients’ groups are shown in Table 1.
Patients had not been treated with drugs which have effects
on vascular remodelling and immunosuppressive agents. Pa-
tients were treated, when required, with diuretics (eight per-
sons), anti-malarial drugs (six patients) and no more than
5 mg/day prednisone equivalent (seven patients). The control
group consisted of 30 healthy volunteers, matched for sex and
age, with no signs of RP.
The Ethical Committee of the Medical University of
Bialystok, Bialystok, Poland, approved the study, and in-
formed consent was obtained from all participants before
entry to the examination.
Clinical and laboratory analysis
Clinical, capillaroscopy and laboratory investigations were
performed on the days of blood sample collection, i.e. 1 week
before the start of treatment and 1 week after the last session
(4 weeks after the first session) of the MLS laser therapy. The
data were collected only during the winter months.
One week before the start of treatment, during the 3 weeks
of the MLS laser therapy, and for 1 week after the end of
exposure sessions, patients were instructed to record any
Raynaud’s attacks in diaries. Number of attacks, the mean
duration of Raynaud’s attack and severity of pain, assessed by
means of a 10-cm visual analogue scale (VAS), had to be
recorded daily at bed time.
Serum samples were frozen at −80 °C immediately after
collection. Examinations included pulmonary and renal func-
tion tests, chest X-ray, renal sonography as well as erythrocyte
sedimentation rate (ESR) and total antinuclear antibodies
(ANA). ANAwere detected by indirect immunofluorescence
on human Hep-2 cell substrate (Viro-Immun Labor
Diagnostica GmbH, Germany) and considered as positive
when a dilution higher than that of 1:80 was obtained. The
serum concentration of VEGF and Ang-2 were determined
using an ELISA kit (Quantikine, R&D Systems). Assays were
performed strictly according to the manufacturers’
instructions.
NVC
NVC was performed in all patients and healthy volunteers
using a stereomicroscope SZ 4045 with a final magnification
of ×200 (Olympus, Germany). A fibre optic light source and
filter provided cold illumination. The optical microscope was
connected to a colour digital camera and a personal computer
with a high-resolution colour monitor (14 in.) (Olympus,
Germany). Four consecutive fields extending over 1 mm in
the middle of the nailfold were studied per finger using image
analysis software (Imaging Software Cell*, Olympus Soft
Imaging Solutions). The images taken at the time of exami-
nation were analyzed by the same experienced investigator
(AKM) without knowledge of the patient’s clinical diagnosis.
The investigator was blinded also referring to the capillary
images recorded as a pre- and post-treatment with MLS laser
therapy.
Each patient was acclimatized for 20 min at room temper-
ature of 20–24 °C prior to the examination. The nailfolds of all
fingers except the thumbs and fingers affected by recent local
trauma were examined in each patient. To obtain the best
visibility of the microvasculature, a drop of immersion oil
was placed on the nailfold bed. Only the capillaries in the
distal row of the nailfold were analyzed.
The intensity of the morphological changes was evaluated
on the basis of semiquantitative method which included the
Table 1 Clinical and capillaroscopic differences in patients with primary and secondary Raynaud’s phenomenon (RP) before MLS laser treatment
Characteristics RP together (n=78) Primary RP (n=38) Secondary RP (n=40) p value
Sex (M/F) 3/75 2/36 1/39 NS
Age (years) (median, range) 43.5 (19–77) 29.5 (19–77) 53.0 (26–66) NS
Disease duration (years, range) 9.0 (1–40) 6.0 (2–40) 12.0 (1–30) NS
Number of RP attacks per week (median, range) 14.0 (1–76) 6.0 (1–76) 20.0 (1–75) <0.02
Mean duration of RP attack (minutes) (median, range) 15.0 (5–120) 15.0 (10–120) 15.0 (5–60) NS
VAS (mm) (median, range) 34.0 (0–96) 19.0 (0–96) 46.0 (0–87) NS
Capillaroscopy score
Score 0 (n/%) 21/26.9 21/55.3 0 <0.001
Score 1 (n/%) 19/24.4 17/44.7 2/5.0 <0.01
Score 2 (n%) 15/19.2 0 15/37.5 <0.01
Score 3 (n/%) 23/29.5 0 23/57.5 <0.001
ANA (n/%) 29/37.2 0 29/72.5 <0.001
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parameters: loop density; capillary length variability; percent
of loops with architectural derangement such as tortuous,
meandering, enlarged/giant, ramified or bushy capillaries;
irregular distribution of the capillary array; and the presence
of extravasations into perivascular tissue. All parameters were
defined on the basis of previous classifications [9, 11] as
follows: dilated capillaries, microvessels with a diameter of
the arterial limb wider than 0.015 mm (=15 μm) or a venous
limb wider than 0.020 mm (=20 μm); giant capillary loops,
homogenously enlarged loops with a diameter wider than
0.050 mm (=50 μm); elongated capillaries, microvessels with
length greater than 0.500 mm (=500 μm); microhemorrhage,
presence of a dark red mass characterized by hemosiderin
deposit derived from capillary injury; tortuosity, a variation
of the typical harpin capillary shape; and avascular area, a
distance between two adjacent capillary loops longer than
0.500 mm (=500 μm). The capillaroscopic findings were
graded according to previous studies [28–30] with modifica-
tions ranging from 0 to 3 where score 0 indicated normal
feature (>8 capillaries/mm, typical hairpin-shaped loops ar-
ranged in parallel rows); 1, mild (6–8 capillaries/mm, <33 %
changed capillary loops with non-homogenous distribution or
size of loops, elongation of the loop or shortened loops and the
absence of haemorrhages); 2, moderate (33–66%morpholog-
ically changed capillaries, enlarged loops, diminished loop
density andmicrohaemorrhages); and 3, severe changes (more
than 66 % dilated capillaries with heterogeneous features of
angiogenesis with a variable capillaroscopic pattern, avascular
areas and microhaemorrhages). The mean score for each
subject was obtained from the analysis of all fingers.
MLS laser therapy
All patients with RP received two-wave MLS laser (ASA
Company) irradiation (808 and 905 nm) 5 days per week
during the period of 3 weeks, with the following parameters:
power 3.3 W (3,300 mW), frequency 1,500 Hz, energy
129.3 J, energy density 1.6 J/cm2 and procedure time
2.5 min on single hand. The laser scanner covered the finger-
tips and the dorsal parts of both hands.
Statistical analysis
The significance of differences between control group and
particular patient groups were tested using Mann–Whitney
rank sum test. Wilcoxon signed rank test was used to evaluate
the differences before and after MLS laser therapy. The prob-
ability of differences in frequency distributions was deter-
mined by the chi-square test or Fisher’s exact test. The data
were correlated by Spearman rank order correlation. p values
lower than 0.05 were considered as statistically significant.
Results
The characteristics of 78 patients with primary and secondary
RP are shown in Table 1. Before the MLS laser therapy, no
significant differences in age, sex, the duration of symptoms
and the pain intensity assessed by visual analogue scale (VAS)
between two groups of patients with primary and secondary
RPwere seen. Themean duration of RP attack in patients with
primary RP was longer, but not significantly, than in the group
with secondary RP (29.6 vs 22.1 min) (Table 1).
After the MLS laser therapy, the number of RP attacks,
their duration and intensity measured by VAS scale was
significantly reduced in the both groups of RP patients
(p<0.001) (Table 2).
NVC patterns of 78 RP patients and 30 healthy volunteers
were examined in this study 1 week before the start of treat-
ment and 1 week after the MLS laser therapy. Before treat-
ment in 21 of 38 (55.3 %) patients with primary RP and in 17
of 38 (44.7 %) persons, normal capillaroscopic pattern and
minor abnormalities (score=1) were found, respectively. All
patients with secondary RP showed abnormalities in
capillaroscopy. In this group, major capillary abnormalities
(score=3) were observed in 23 of 40 (57.5 %) patients,
moderate changes (score=2) were present in 15 of 40
(37.5 %) and, finally, 2 of 40 (5 %) persons had minor
abnormalities (Table 1).
The capillaroscopic feature in the control group showed
hairpin capillaries in a parallel arrangement. In isolated tortu-
ous capillary loops and meandering, elongated capillaries
were found in four persons (13.3 %) of the healthy volunteers.
ANAwere detected in 29 patients and were present only in the
group with secondary RP (72.5 %).
After the MLS laser therapy, the number of patients with
primary RP and normal capillaroscopic patterns increased
from 21 (55.3 %) to 29 (73.7 %) persons. Furthermore, in
patients with secondary RP, a reduction of the number of
patients with severe capillaroscopic abnormalities from 23
(57.5 %) to 17 (42.5 %) cases was observed. Moreover, in
seven from 15 patients with moderate changes (score=2), an
increase of capillaroscopic images with regular distribution
and normal capillary density was found. After the MLS laser
therapy in 14 of 40 (35 %) patients with secondary RP, an
increase in the loop number and a reduction in avascular areas,
capillary alterations and microhaemorrhages in capillaroscopy
were observed (data not shown).
Serum levels of VEGF and Ang-2 concentrations were
determined in 78 RP patients, including 38 patients with
primary RP and 40 cases with secondary RP, and in 30 healthy
volunteers. The RP patients had significantly elevated con-
centrations of VEGF and Ang-2 compared with age-matched
healthy volunteers (p<0.05, p<0.001, respectively). Before
the MLS laser therapy, the serum concentrations of VEGF
(p<0.05) and Ang-2 (p<0.001) were significantly higher in
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patients with secondary RP in comparison to the group with
primary RP (data not shown). After the MLS laser therapy,
serum Ang-2 levels decreased statistically significant in pa-
tients with primary and secondary RP compared with the
values before the treatment. In contrary, no significant differ-
ences of VEGF serum concentrations between the RP patients
before and after MLS laser therapy were found (Figs. 1 and 2).
Before the therapy, RP patients with severe and moderate
changes in nailfold capillaroscopy (score >1) showed higher
VEGF and Ang-2 serum levels than persons without or with
mild changes; however, no significant differences were ob-
served (data not shown). After the MLS laser therapy, serum
levels of Ang-2 were significantly lower than before the
treatment in all RP groups according to capillaroscopic score
(p<0.05 according to scores 0, 1 and 2 and p<0.001 in
patients with score=3) (data not shown).
In patients with primary RP, significant positive correlation
between duration of attack and the intensity of pain (according
to VAS scale) was observed (r=0.65, p<0.001). Before the
treatment, a significant positive correlation between the mi-
crovascular changes in NVC and the number of RP attacks
(r=0.24, p<0.05) as well as the intensity of pain measured by
VAS scale (r=0.27, p<0.02) in patients with primary and
secondary RP was found. After the MLS laser therapy, the
severity of capillaroscopic abnormalities correlated signifi-
cantly with the intensity of RP attack (r=0.23, p<0.05).
Moreover, Ang-2 serum level was positively correlated to
the duration of RP (r=0.42, p<0.01) and negatively to the
duration of RP attack (r=−0.34, p<0.05) (data not shown).
Discussion
Although RP can be manifested clinically as an isolated, acute
vascular disorder with a benign course, it may precede the
future development of systemic connective tissue diseases
leading to serious complications associated with reduced qual-
ity of life and shortened life expectancy [28, 31–33]. Proposed
therapeutic interventions in RP include a broad spectrum of
therapies, from pharmacological treatment to surgery, re-
served for complicated conditions [13, 14]. The unsuccessful
effects and limitations of the pharmacological treatment are
the reason of searching for new therapeutical methods, such as
non-pharmacologic therapy [15, 16]. One of these methods is
new a technique of laser irradiation—MLS laser therapy
consisted of synchronized generation of two-wave laser radi-
ation leading to analgesic, anti-inflammatory and anti-oedema
effects [18, 19]. However, no studies exist on the relationship
between the clinical effectiveness of MLS laser therapy, mi-
crovascular abnormalities in NVC and immunological param-
eters of endothelial cell damage in patients with primary and
secondary RP.
In the present study, after 3 weeks ofMLS laser therapy, the
clinical improvement manifested by decreasing of the number
of RP attacks, duration of Raynaud’s attack and pain intensity
measured by VAS scale in both groups of RP patients was
observed. The effectiveness of MLS laser therapy has also
been observed in knee osteoarthritis [18]. In placebo-
controlled double-blind intervention study, a reduced frequen-
cy and intensity of attacks in patients with primary Raynaud’s
phenomenon after 3 weeks of low-level laser therapy (LLLT)
has been demonstrated; however, the mechanisms of these
Table 2 Clinical characteristics of patients with primary and secondary Raynaud’s phenomenon (RP) before and after MLS laser therapy
Primary RP p value Secondary RP p value
Number of RP attacks per week (median, range) Before MLS laser therapy 6.0 (1–76) <0.001 20.0 (1–75) <0.001
After MLS laser therapy 5.0 (0–35) 15.0 (0–70)
Mean duration of RP attack (min) (median, range) Before MLS laser therapy 15.0 (10–120) <0.001 15.0 (5–60) <0.001
After MLS laser therapy 12.5 (0–60) 10.0 (0–60)
VAS (mm) (median, range) Before MLS therapy 19.0 (0–96) <0.001 46.0 (0–87) <0.001
After MLS laser therapy 14.5 (0–68) 31.0 (0–71)
Fig. 1 Serum concentrations of vascular endothelial growth factor
(VEGF) in RP patients before and after MLS laser therapy assessed by
ELISA technique. Box plots represent median (line), 25th and 75th
percentiles (box) and 10th and 90th percentiles (whiskers). Significance
of differences between control group and particular subgroups of patients
were expressed as *p<0.05, ***p<0.001
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effects remain unclear [16]. Moreover, a significant improve-
ment of LLL treatment in primary and secondary RP patients
after 6 weeks and 3 months was noticed [17]. The results of
clinical effectiveness of laser therapy reported in mentioned
studies are difficult to compare with our findings because of
using various application methods and different therapy reg-
iments with different doses, power and wavelengths.
It has been postulated that laser therapy might improve the
endothelial function in patients with RP [17]. Although the
effectiveness of laser therapy was clinically and thermograph-
ically demonstrated in RP patients, no studies analyzing the
influence of the MLS treatment on the microvascular abnor-
malities in NVC exist [16, 17].
In the present study, NVC was used as a non-invasive
method for investigating the microvascular abnormalities in
RP patients [31]. In this study, 55.3 % of patients with primary
RP showed a normal capillaroscopic pattern, and in 44.7 % of
cases, minor vascular abnormalities were found. In the group
with secondary RP, major capillary abnormalities were ob-
served in 57.5 % patients, moderate changes in 37.5 % and
5 % persons had minor abnormalities. These results are in
agreement with other reports, indicating significant differ-
ences between the capillaroscopic patterns in patients with
primary and secondary RP [9, 29].
A broad spectrum of capillaroscopic findings associated
with RP ranging from a normal pattern to microvascular
abnormalities and the lack of guidelines for the ill-defined
normal range of capillaroscopic changes are the limiting fac-
tors for the precise interpretation of capillaroscopic patterns
[9]. On the other hand, in the literature, a good reproducibility
of the qualitative evaluation was found [30]. Furthermore, the
importance of capillaroscopy for identifying RP patients at
high risk for the development of scleroderma spectrum dis-
eases was demonstrated [10]. Additionally, a prognostic
screening model for RP, which could help to stratify the risk
of transition to SSc and to plan an appropriate clinical strategy,
was proposed [28].
In our study, after MLS laser therapy in 18.4 % of RP
patients with mild changes in NVC, an increase of morpho-
logically unchanged, regular distributed loops was found.
Moreover, in seven from 15 patients with moderate changes,
an increase of capillaroscopic images with regular distribution
and normal capillary density was observed. Furthermore, after
MLS laser therapy in 14 of 40 (35 %) patients with secondary
RP, an increase in the loop number and a reduction in avas-
cular areas, capillary alterations and microhaemorrhages in
NVC were demonstrated.
These findings may confirm the observations of other
authors who reported that the endothelium-mediated dilatation
of the brachial artery in patients with primary RP can be
improved by laser therapy [17]. Although LLLT appears to
be an effective treatment in RP patients, different therapeutic
effects based on the heterogeneity of the clinical presentation
of primary RP have been suggested [16].
The positive effect of MLS therapy on NVC pattern is
possible, taking into consideration the results of several find-
ings, suggesting a modulating effect of bosentan [34] or
immunosuppressive therapy on scleroderma NVC pattern
[27, 35].
In the present study, we demonstrated a significant clinical
improvement of MLS laser therapy in patients with primary
and secondary RP. According to Gladue, self-reported assess-
ment of RP severity is associated with the possibility of
placebo responses [36]. However, a combination of outcome
measures could diminish the placebo response. In this study,
the clinical assessment included the number of attacks, the
mean duration of Raynaud’s attack and severity of pain,
according to the visual analogue scale. Moreover, after the
MLS laser treatment, the development of nailfold
microvascularization, characterized by an increase in the loop
number with regular distribution and normal capillary density
a nd a r e du c t i o n i n c ap i l l a r y a l t e r a t i o n s a nd
microhaemorrhages in NVC, were observed in 35 % of pa-
tients with secondary RP.
Recently, many studies have concentrated on the role of
angiogenesis and microvascular endothelial injury in the path-
ogenesis of RP [2]. Dysfunction of microcirculation in the
course of RP is associated with homeostasis disturbances
between pro- and anti-angiogenic factors, resulting in the
impaired vasodilation and the initiation of angiogenesis [2].
Increased production of VEGF and Ang-2 has been demon-
strated in various conditions in which vascular pathology is
related to endothelial cell activation [37]. In our previous
study, we demonstrated a relationship between capillaroscopic
abnormalities, serum VEGF concentrations and other endo-
thelial cell activation markers and clinical manifestation in
SLE patients [10, 38].
Fig. 2 Serum concentrations of angiopoietin 2 (Ang-2) determined and
presented as described in the legend of Fig. 1
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Now, we demonstrated that the VEGF serum concentration
was significantly higher in patients with primary and second-
ary RP compared to healthy volunteers. Moreover, the mean
serum concentration of VEGF did not differ significantly
between patients with primary and secondary RP before and
after MLS laser therapy. In our previous study, we demon-
strated significantly higher serum levels of VEGF in SLE
patients with severe and moderate microvascular changes
compared with patients with mild capillaroscopic abnormali-
ties [11]. Although the results of this study in RP patients
confirm that in patients with severe and moderate changes, the
serum concentration of VEGF is higher than in patients with
mild microvascular abnormalities; no significant differences
were demonstrated.
Ang-2 and VEGF coordinately regulate endothelial behav-
iour. In the presence of VEGF, Ang-2 enables migration and
proliferation of endothelial cells and the sprouting of new
blood vessels, whereas the presence of Ang-2 leads to the
endothelial cell death and vessel regression if the activity of
VEGF is inhibited [3]. In previous reports, Ang-2 is shown to
be a key serum marker reflecting the activity and severity of
vascular diseases [4].
In the present study, the Ang-2 serum concentration was
higher in patients with primary and secondary RP compared
with healthy volunteers. Moreover, after the MLS laser ther-
apy, a significant decrease of the mean Ang-2 serum levels in
patients with primary and secondary RP was demonstrated.
Several studies have shown increased Ang-2 concentrations in
vascular diseases, including systemic sclerosis (SSc), [39]
compared to healthy volunteers. It is postulated that serum
level of Ang-2 is a useful marker to evaluate the activity and
severity of systemic sclerosis [39]. Furthermore, clinical stud-
ies have shown that vasculopathy associated with the eleva-
tion of serum Ang-2 levels reflects the inflammatory process
underlying high SSc activity [39]. The results of this study
confirm the relation between the Ang-2 serum levels and the
clinical and microvascular findings after MLS laser therapy in
RP patients.
In this study, we investigated the influence of MLS laser
therapy on clinical features, microvascular changes in nailfold
videocapillaroscopy and circulating modulators releasing as a
consequence of vascular endothelium injury such as VEGF
and Ang-2 in patients with primary and secondary Raynaud’s
phenomenon.
Our results suggest that MLS laser therapy showed bene-
ficial clinical effects manifested by a decrease of duration and
number of RP attacks as well as a degree of pain score in VAS
scale after 3 weeks of therapy in patients with primary and
secondary RP. Furthermore, the correlation between the num-
ber of RP attacks and intensity of pain with the microvascular
changes in NVC observed in this study may confirm the
association between severity of the capillaroscopic abnormal-
ities and progression of the disease. Moreover, the tendency of
normalization of Ang-2 concentration in the serum of primary
and secondary RP patients may suggest favourable effect of
MLS therapy on regulation of processes involved in micro-
vascular disorders.
Our data suggest that MLS laser therapy shows beneficial
clinical effects in patients with primary and secondary RP.
Furthermore, NVC may reflect microvascular abnormalities
associated with clinical improvement after MLS laser therapy
RP patients. Moreover, Ang-2 serum level may be a useful
marker of microvascular abnormalities in RP patients treated
with MLS therapy.
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